TD Cowen analyst Tara Bancroft has maintained their neutral stance on FATE stock, giving a Hold rating on March 7.
Tara Bancroft’s rating is based on the current developments and future prospects of Fate Therapeutics. The company is actively working on expanding its FT819 program, particularly in the treatment of systemic lupus erythematosus (SLE), with updates expected at major conferences in 2025. The early data from the initial patients treated with FT819 have shown promising results in terms of disease remission and safety, which is encouraging for future trials.
However, despite these positive developments, there are still uncertainties regarding the broader application and long-term outcomes of their therapies. Fate Therapeutics is also in the process of evaluating other potential treatments, such as CAR-iNK FT522 and FT825, which are still in the early phases of development. These factors contribute to a cautious outlook, justifying a Hold rating as the company continues to advance its clinical programs and gather more comprehensive data.
In another report released on March 7, Bank of America Securities also maintained a Hold rating on the stock with a $2.50 price target.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of FATE in relation to earlier this year.